Sign In
Buy ALPMF
$13.25
-0.473 (-3.44%)
At Close: Jun 03, 2026
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
12:31am, Tuesday, 28'th Apr 2026
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
06:22pm, Monday, 06'th Apr 2026
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
01:30pm, Tuesday, 24'th Feb 2026
Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at hi
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechn
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
10:14pm, Monday, 09'th Feb 2026
Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue selling the product
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
09:16pm, Monday, 12'th Jan 2026
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript
06:02pm, Saturday, 26'th Apr 2025
Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2024 Earnings Conference Call April 25, 2025 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Naoki Okamura - Representative
Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward
09:56am, Saturday, 15'th Mar 2025
Astellas Pharma Inc. has a diverse pipeline with significant growth in oncology, driven by new approvals for drugs like zolbetuximab. Despite recent stock declines, ALPMF's revenue and core profits ha
Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript
01:51pm, Saturday, 08'th Feb 2025
Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2024 Earnings Conference Call February 4, 2025 2:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IR Officer Atsushi Kitamura - Chief Fina
Astellas Pharma Inc. (ALPMF) Q1 2024 Earnings Call Transcript
12:19pm, Saturday, 03'rd Aug 2024
Astellas Pharma Inc. (OTCPK:ALPMF) Q1 2024 Earnings Conference Call August 1, 2024 3:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IRO Tadaaki Taniguchi - CMO Claus Zieler -
Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
06:00pm, Friday, 26'th Apr 2024
Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2023 Results Conference Call April 25, 2024 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and Investor Relations Officer Naoki Okamura -
- Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival vs platinum-containing chemotherapy- - If approved, enfortumab
Astellas Pharma Inc. (ALPMF) Q3 2023 Earnings Call Transcript
01:08pm, Monday, 05'th Feb 2024
Astellas Pharma Inc. (ALPMF) Q3 2023 Earnings Call Transcript
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
06:35pm, Sunday, 17'th Dec 2023
- Astellas contributed to the development of a pediatric formulation to treat schistosomiasis as a member of the Pediatric Praziquantel Consortium - TOKYO , Dec. 17, 2023 /PRNewswire/ -- Astellas Phar
Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
12:06am, Thursday, 02'nd Nov 2023
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call November 1, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy & Relations Atsushi Kitamura - Chief Fin
